Organon & Co.
Company Name | Organon & Co. |
Stock Symbol | OGN |
Class Period | October 31, 2024 to April 30, 2025 |
Lead Plaintiff Motion Deadline | July 22, 2025 |
On May 1, 2025, Organon released its first quarter 2025 financial results, announcing that management had reset the Company’s dividend payout, from $0.28 to $0.02 and would “redirect those funds to debt reduction.”
On this news, Organon’s stock price fell $3.48, or 26.9%, to close at $9.45 per share on May 1, 2025, thereby injuring investors.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Organon’s optimistic reports of the dividend payout as the Company’s “number one priority,” were offset by Organon’s newly implemented debt reduction strategy, thus, leading to a drastic decrease – over 70% – of the quarterly dividend; (2) Organon planned to prioritize debt reduction following the Company’s acquisition of Dermavant; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Submit Your Information
If you suffered a loss on your Organon & Co. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.